Foundation Capital leads the Series A, with participation from Citi and HSBC

NEW YORK and SINGAPORE, Sept. 24, 2026 — IPID, the payment intelligence company helping institutions know who they are paying, announced a $16 million Series A led by Foundation Capital, with participation from strategic investors Citi and HSBC. The round also includes existing investors QED Investors, Monk’s Hill Ventures and Quona Capital.

Digital payments have become faster and more seamless, but the information needed to evaluate them has not always kept pace. Institutions still do not always know who is receiving a payment or have enough information to assess risk before it is sent. The burden often falls on the sender to confirm the recipient, even when that sender may be the target of a scam. According to LSEG, Authorized Push Payment fraud alone is projected to cause $331 billion in global losses by 2027.

IPID is a leading global provider of bank account verification, supporting major financial institutions across more than 50 countries. It will soon expand its platform by applying its expertise in fragmented payment markets to U.S. payments and digital assets, giving institutions the intelligence to make the right decision before funds move.

“Every payment starts with a decision, but institutions are often making that decision with incomplete information,” said Damien Dugauquier, co-founder and CEO of IPID. “We started by solving bank account verification globally. We are now building the broader decision intelligence that institutions need before funds move – across countries, payment rails and forms of value. The future of payments will not be defined simply by moving money faster. It will be defined by making better decisions before money moves.”

“IPID has rapidly become the global standard for bank account verification and intelligence. It’s quite a feat for something like this to develop outside of a bank consortium and makes IPID uniquely well-positioned to help financial institutions and payors globally fight fraud and streamline payment operations,” said Zach Noorani, Partner at Foundation Capital.

Payments are becoming faster and more automated as real-time payments scale, new rails emerge and AI agents begin to initiate transactions. But the information institutions need before executing a payment remains fragmented across markets, providers and rails. IPID is tackling that blind spot by helping institutions know who is behind the receiving account before a payment becomes final.

“In an increasingly digital and interconnected financial landscape, it is critical to have payment validation that is instantaneous and highly secure. Our strategic alignment with IPID  is further deepened through our participation in their Series A raise. We are excited at IPID’s ability to deliver a globally consistent, high-performance experience that helps our clients continue to optimize their international operations with confidence,” said Bis Chatterjee, Global Head, Partnerships and Innovation for Citi‘s Services.

Tom Simpson, Global Head of Currency Clearing & North America Regional Head of Cross Border Payments, Global Payment Solutions, HSBC, said: “HSBC’s arrangement with IPID helps us extend beneficiary validation beyond local scheme requirements and provide clients with more information when making payments. This can help improve efficiency and certainty in an increasingly dynamic payments ecosystem.”

IPID will use the funding to deepen its global payment intelligence network, accelerate growth in the United States and Europe, and develop new capabilities that help institutions make more informed decisions and streamline payment operations before funds move across U.S. payment rails, stablecoins and digital assets.

About IPID

IPID provides decision intelligence for banks, PSPs, platforms and corporates moving money. Across the payment lifecycle, IPID helps them verify payees and assess fraud risk, meet regulatory obligations, assess risk, monetise payments and enrich payment data. This gives them certainty, control and safety with reduced fraud, lower operational costs and a better customer experience follows. www.ipid.tech  

SOURCE INTERNATIONAL PAYMENTS IDENTITY (IPID) PTE. LTD.

Richmond based investment bank’s new name reflects its emphasis on guiding founders through the full arc of a transaction — including what happens after the deal closes.

RICHMOND, Va., Sept. 24, 2026 — Transact Capital, a licensed investment bank and member of FINRA and SIPC specializing in mergers and acquisitions for founder-led, lower-middle-market businesses, today announced it has rebranded as Sequel Advisors. The change reflects the firm’s approach to M&A advisory: helping founders navigate not just the transaction itself, but the outcome that follows it.

Founded in 2003 and based in Richmond, Virginia, Sequel Advisors is a boutique firm advising founders primarily on sell-side M&A transactions, with a core focus on business services and growing practice areas in technology, healthcare, industrials, and adjacent sectors. Many of the firm’s team members are former founders and operators themselves.

“Why rebrand? The firm we’ve become deserves a name that actually describes it, and because the founders we serve deserve to know exactly what they’re getting before they ever pick up the phone. Our name now matches the way we’ve always done the work ” said Patrick Morin, Managing Partner at Sequel Advisors.

The rebrand includes a new visual identity and a redesigned website, sequeladvisors.com, featuring an expanded collection of client case studies detailing founders’ experiences working with the firm from engagement through post-close. The firm’s leadership, team, and day-to-day operations remain unchanged. Learn more about the team here.

About Sequel Advisors
Sequel Advisors is a licensed investment bank and member of FINRA and SIPC advising founder-led businesses globally across business services, technology, healthcare and industrials through mergers, acquisitions, and recapitalizations. Founded in 2003 and headquartered in Richmond, Virginia, the firm works with founders on transactions typically ranging from $20 million to $250 million in enterprise value. Learn more at sequeladvisors.com.

Media Contact
Susan Clark
Director of Operations
Sequel Advisors
[email protected]
804-612-7108

SOURCE Sequel Advisors, LLC

Samantha Moore, Jessica Merriam and Nicole Gibson to lead customer-focused business groups

RESTON, Va., Sept. 24, 2026 — Quantum Sky today announced the appointment of three executive vice presidents to lead its newly aligned customer-focused business groups: Department of War, Intel & Space and Federal Civilian. The appointments are part of a broader operating structure designed to strengthen alignment across Growth, Technology and Operations and better position the company to serve customers across its core federal markets.

Samantha Moore will serve as executive vice president of the Department of War Business Group, Jessica Merriam as executive vice president of the Intel & Space Business Group and Nicole Gibson as executive vice president of the Federal Civilian Business Group.

“As Quantum Sky continues to grow, we have an opportunity to align our people, technology and operations even more closely around our customers and their missions,” said Andrew Boyd, CEO of Quantum Sky. “Samantha, Jessica and Nicole bring deep market expertise, strong operational leadership and proven track records of leading organizations that deliver mission outcomes. This structure gives us greater focus as we bring the full breadth of Quantum Sky’s capabilities to our customers.”

Moore leads the Department of War Business Group. She brings more than 20 years of experience across defense, intelligence and cloud markets, most recently serving as vice president, Department of War, at SMX. She previously held senior leadership roles at Amazon Web Services and spent more than a decade with Peraton and predecessor company Solers supporting space, intelligence and defense missions.

Merriam leads Quantum Sky’s Intel & Space Business Group. She joined the company from SilverEdge Government Solutions’ Intelligence Solutions Group, later acquired by SAIC, where she led an intelligence business supporting Intelligence Community customers, DIA, and SOCOM. She previously served as executive director of Intelligence Community programs at CACI and completed a military career spanning more than 20 years as an intelligence officer, including assignments within Joint Special Operations Command and the National Security Council.

Gibson leads Quantum Sky’s Federal Civilian Business Group and brings more than 25 years of experience in enterprise transformation, operational excellence and business growth. She most recently worked with Guidehouse’s senior leadership team on enterprise transformation and previously spent 10 years as a partner at PwC and Guidehouse, where she led Intelligence Community and Office of the Secretary of War portfolios.

“Quantum Sky is entering an important next phase of growth, and this leadership structure is built to support that momentum,” said Michael Lustbader, a Managing Partner at Arlington Capital Partners. “Together, Arlington and Quantum Sky are investing in quantum computing and other differentiated technologies to support the company’s expansion across key federal markets and deliver enduring value for its customers and their missions.”

About Quantum Sky

Quantum Sky, formerly Tyto Athene, is a mission technology company that builds secure, AI-enabled and quantum-ready capabilities for defense, intelligence and federal civilian agencies. By combining trusted government delivery with applied AI, post-quantum readiness and emerging quantum research, Quantum Sky helps customers modernize critical systems, secure mission data and operate with greater speed, resilience and confidence.

At the core of its model is Project 137, an applied innovation and intellectual property engine that turns emerging technology into fielded mission advantage. Headquartered in Reston, Va., Quantum Sky engineers practical advantage for high-consequence missions. For more information, visit quantumsky.com.

About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-area private investment firm specializing in government-regulated industries. Focused on the aerospace and defense, government services and technology, and healthcare sectors, the firm partners with founders and entrepreneurs to build platforms of strategic importance to national priorities.

Operating in markets with high barriers to entry, Arlington looks to partner with organizations within these industries that save lives, improve effectiveness and reduce costs. Since inception in 1999, Arlington has invested in over 200 companies, raised over $14 billion in committed capital, and is currently investing out of its $6 billion Fund VII.

SOURCE Quantum Sky

Investment for a 4.9% minority stake implies an approximately $1 billion post-money valuation for the Slovenian technology company.

HONG KONG and LJUBLJANA, Slovenia, Sept. 24, 2026 — Windsor Capital today announced the completion of a $50 million strategic investment in Space Labs d.o.o., a Slovenian technology company developing proprietary protocols, blockchain infrastructure and digital economic systems for real-world applications.

The investment was made for a 4.9% minority interest in Space Labs, implying a post-money valuation of approximately $1.02 billion.

The transaction concludes a process spanning more than two years, including completion of contractual milestones and financial, technical and legal due diligence.

The $50 million in primary capital will support Space Labs’ international expansion and accelerate development of its technology infrastructure and real-world applications.

At the center of Space Labs’ technology is the RWD Protocol – Real World Digitalization Protocol, designed to connect real-world projects and businesses with capital and global communities through blockchain, smart contracts and transparent digital processes. Rather than simply tokenizing assets, RWD is designed to digitalize participation itself.

As an initial commercial collaboration, Space Labs and Windsor Capital are developing a vehicle distribution channel through Windsor’s international automotive and industrial network, with phased distribution across multiple international markets.

“This partnership is about much more than capital. The $50 million investment gives Space Labs financial strength, while Windsor brings global relationships and real-world opportunities into the technology infrastructure we have built,” said Igor Šinkovec, Founder and CEO of Space Labs.

“Space Labs has built technology addressing a global opportunity. Combined with Windsor’s international network, we believe this partnership can create something significantly larger than either side could build independently,” said John M. Probandt, Chairman, Founder and CEO of Windsor Capital.

About Space Labs

Space Labs d.o.o. is a Slovenian technology company developing proprietary protocols, blockchain infrastructure, smart contracts and digital economic systems for real-world applications, including the RWD Protocol and SpaceM technology ecosystem.

spacelabs.si

About Windsor Capital

Windsor Capital is a Hong Kong-headquartered diversified group with interests across automotive, advanced manufacturing, biotech and international supply chains.

windsorcapital.net 
windsor.business
www.windsorprestigecoltd.com

Forward-Looking Statements 

This release contains forward-looking statements subject to risks and uncertainties. Actual results may differ materially from expectations. Nothing herein constitutes an offer or solicitation to buy or sell any security or financial instrument.

Photo: https://mma.prnewswire.com/media/3009061/Space_Labs.jpg
Logo:  https://mma.prnewswire.com/media/3009062/Space_Labs_Logo.jpg

Miami-headquartered company brings its American and British operations under one brand and one proprietary platform, following 1,000% application volume growth in its US Instant funding product and ahead of new products planned for 2027.

MIAMI, Sept. 24, 2026 — Cashera today announced its arrival as a unified global funder serving small businesses, independent contractors, e-commerce sellers and established businesses across the United States and the United Kingdom, consolidating operations previously conducted as Cashera Capital in the US and Cashera in the UK under a single brand, a single leadership team and a shared technology strategy. The company also launched its new corporate site at Cashera.com.

The consolidation follows a period of rapid growth in the company’s US business. Cashera Instant application volume has grown by 1,000% since January 2026. Instant provides automated cash flow financing to independent contractors and micro-business operators. The application takes approximately five minutes, and decisions are returned in minutes, around the clock.

The name is new. The team is not. Cashera’s executives have worked together for over a decade in small business finance. In the past eighteen months alone, that same group built the proprietary systems and automated underwriting behind Cashera Instant in the United States while standing up the company’s United Kingdom operation in parallel.

“We are building Cashera as a technology company first,” said Mark Allayev, Founder and CEO of Cashera. “We have invested heavily in our technology team and proprietary infrastructure with one goal: to make access to capital faster, simpler and ultimately seamless and instant. Cashera Instant is already live in the US, and in 2027 we plan to bring that technology and instant decisioning experience into the UK. At the same time, we are developing Cashera Flow to provide instant approval for flexible lines of capital, together with a mobile experience that makes accessing and managing capital as seamless as possible. Bringing everything under one brand gives us the platform to continue building financial products around how businesses actually operate today.”

One technology platform, two markets

Cashera’s platform is built around Apolo, its proprietary underwriting and decisioning engine. Apolo spans the infrastructure behind Cashera’s products, from data analysis and risk assessment through to approval. Today, it powers the automated decisioning behind Cashera Instant in the United States.

At the core of Apolo is Cashera’s own scoring model, which evaluates transaction-level data together with multiple additional data points through internally developed algorithms and machine-learning models. Rather than relying primarily on traditional credit history, Apolo is designed to build a more current and dynamic view of an applicant’s financial activity, cash flow and overall profile, helping Cashera make faster and more consistent funding decisions.

The platform is designed to become increasingly automated as Cashera expands its products, allowing applications to move from data analysis and scoring through decisioning and approval with significantly less manual intervention.

Growth through partners

Cashera distributes its products almost entirely through referral partners rather than a direct sales force. Every partner receives a dedicated dashboard and co-branded, UTM-tagged links so traffic, applications, offers and funded deals are attributed to the originating partner and visible in real time.

“My background is on the broker marketplace side, so I knew exactly what partners never get, which is visibility,” said Mike Assim, Head of Partnerships at Cashera. “Working with our product team, we pushed the real-time partner dashboard forward fast. Transparency compounds. It is why this channel grew without a sales floor.”

Prospective partners can register at Cashera.com/partners or contact [email protected].

Products across both markets

In the United Kingdom, Cashera’s Growth product currently provides unsecured business loans from £5,000 to £300,000 to established companies across retail, hospitality, motor trade, beauty, e-commerce and healthcare, supported by a dedicated London team.

Cashera plans in the near term to expand Growth to provide funding of up to £500,000 per deal.

In 2027, Cashera plans to bring the automated technology behind Cashera Instant into the UK. The UK Instant product is expected to provide funding of up to £10,000, with plans to provide returning customers with access to up to £20,000.

Building the next generation of Cashera products

Cashera also confirmed that Cashera Flow, a product offering a flexible line of capital, is in development for a 2027 launch in both the United States and the United Kingdom.

Cashera Flow is being designed around Cashera’s proprietary platform to provide instant approval for flexible lines of capital, extending automated decisioning beyond individual funding transactions into an ongoing capital product.

As part of the Flow launch, Cashera is developing dedicated iOS and Android applications designed to provide a seamless user experience for customers accessing and managing their lines of capital.

Alongside the expansion of Cashera Instant into the UK, the company’s 2027 roadmap is designed to extend its proprietary scoring, machine learning and automated decisioning capability across a broader range of products and customers in both markets.

Expanding the leadership team

Cashera’s engineering is led by Chief Technology Officer Apolo Doca, who oversees the company’s platform and the continued development of its proprietary decisioning infrastructure.

Cashera recently appointed Aravind Muralidharan as Head of Risk. He brings experience from Kabbage, American Express and Zip, a global buy-now-pay-later provider. His background will support the continued development and refinement of Cashera’s credit models, risk strategy and automated decisioning capabilities as the company expands its products across the US and UK.

Cashera also appointed Roman Sukharenko as Head of Marketing. He brings 16 years of experience and a background working with Fortune 500 brands internationally.

Leadership

Cashera is led by Founder and CEO Mark Allayev, Chief Operating Officer Paul Vega, Chief Financial Officer Matt Schulman and Chief Technology Officer Apolo Doca.

United Kingdom commercial operations are led by Chief Commercial Officer Jeremy Crinall and Head of Business Development Stephen Yearwood.

About Cashera

Cashera is a technology company and funder serving small businesses, independent contractors, e-commerce sellers and established businesses in the United States and the United Kingdom. Cashera is headquartered in Miami, with UK operations in London. Learn more at Cashera.com.

Partner With Cashera

Cashera is expanding its US referral partner network across ISOs, brokers, lead generation platforms, gig economy marketplaces and 1099 workforce apps. Become a Partner

Media and Partner Contact

Mike Assim
Head of Partnerships
Cashera
[email protected]
Cashera.com/Partners

SOURCE Cashera

SCOTTSDALE, Ariz., Sept. 24, 2026 — Jetstream Venture Fund (Jetstream), an innovative interval fund dedicated to opening access to institutional-grade deal flow for a wider mainstream audience, today announced a strategic investment in Rejuvenation Technologies. The biotechnology company is pioneering targeted mRNA therapies designed to extend telomeres, aiming to restore cellular regenerative capacity and treat severe age-related diseases.

This addition solidifies Jetstream’s position at the forefront of longevity science, life extension, and advanced gene therapy. Rejuvenation Technologies joins recent Jetstream portfolio additions Rejuvenate Bio (a Harvard-spun gene therapy company backed by Merck Animal Health), and Wonderlab Bio, a pioneer in off-the-shelf cell therapies. Together, these investments create a cohesive, high-growth portfolio, granting everyday retail investors access to the future of human healthspan and cellular repair.

Born out of foundational research at Stanford University by CEO and co-inventor Dr. John Ramunas, Rejuvenation Technologies utilizes modified mRNA delivered via proprietary lipid nanoparticles to specific organs. Unlike permanent telomerase activation, this transient approach temporarily extends telomeres to reverse years of cellular aging in a single day.

Backed by top-tier institutional investors, including Khosla Ventures and Y Combinator, and supported by over $8 million in non-dilutive grants from the NIH and CIRM, the company is rapidly advancing preclinical pipelines targeting idiopathic pulmonary fibrosis and severe chronic liver disease.

“Rejuvenation Technologies represents the kind of highly technical, paradigm-shifting science Jetstream seeks to identify early,” said Chris Yoo, Fund Manager at Jetstream. “By adding their breakthrough mRNA platform alongside our existing stakes in Rejuvenate Bio and Wonderlab Bio, we are thrilled to offer our investors a seat at the table for disruptive technologies that could fundamentally alter how we treat chronic, age-related diseases.”

By securing early-stage access to companies addressing massive gaps in regenerative medicine, Jetstream continues to break down the barriers of venture capital to everyday investors.

About Jetstream Venture Fund Jetstream Venture Fund is an interval fund managed by Xcellerant Ventures and Sweater Industries LLC, seeking to provide investors access to high-growth companies with lower minimums and no carried interest. To learn more or view current portfolio data, visit https://www.jvf.vc.

Disclosure: Investors should carefully consider the investment objectives, risks, charges, and expenses before investing. The prospectus contains this information and can be obtained by visiting https://www.jvf.vc. Please read carefully before investing.

Media Contact: Dawson Fearnow, [email protected] 

SOURCE Jetstream Venture Fund

Francisco Partners leads investment as nearly 10% of the Fortune 500 have moved pharmacy benefits to Rightway’s aligned model.

NEW YORK, Sept. 24, 2026 — Rightway, a pharmacy benefit management and care navigation company, today announced that it has raised $155 million in Series E financing led by Francisco Partners, a leading global investment firm that specializes in partnering with technology companies, with participation from existing investors Thrive Capital and Khosla Ventures. The investment will support Rightway’s next phase of growth as employers seek greater accountability for pharmacy spending and better support for their members.

Healthcare costs continue to rise faster than inflation, and prescription drugs are projected to be the fastest-growing major category of healthcare spending over the next decade. In 2025, prescription drug spending increased 9.4% among large U.S. employers, outpacing the 6% increase in overall health benefit costs. Employers are paying for bloated administrative overhead and a set of incentives that reward the middle of the supply chain when drug prices go up rather than down. Rightway’s model offers one of the clearest opportunities to change that trajectory by managing costs more effectively while improving the care people receive.

Rightway now counts 45 Fortune 500 companies among its clients. Its approach combines an aligned financial model that removes all incentives to profit from higher drug spend with a clinical model that puts pharmacists to work guiding members to the most appropriate medications at the lowest cost. The company’s care navigation offering extends that model across healthcare, helping members find high-quality care and get more from their benefits. Plan sponsors partner with Rightway to deliver more value from every healthcare dollar for their organizations and their members.

Rightway backs that financial alignment with its SureSpend™ model. The Precision Pricing Guarantee sets a maximum on total pharmacy spend. The Zero-Markup Wrap covers categories commonly excluded from pharmacy spending guarantees, including GLP-1s and rare high-cost medications, at true net cost with 100% rebate pass-through.

“No one is better positioned to manage the pharmacy benefit than Rightway,” said Jordan Feldman, Rightway’s Co-Founder and CEO. “We built our financial model to reward getting members onto high-value drugs, and we embedded clinicians in the workflow and AI on the backend to do it. If we can help employers get more from one of their largest and fastest-growing healthcare expenses, we make healthcare more affordable for companies and the people who work for them.”

Rightway will use the Series E financing to expand its AI capabilities and the technology that powers its pharmacy benefits model. “The pharmacy supply chain carries a lot of cost that has nothing to do with the medication itself,” said Feldman. “Our technology and AI pull costs out of a bloated ecosystem that has failed to be efficient and transparent. That combination of better economics, better technology, and human clinical expertise means better care for members and lower costs for employers.”

“Pharmacists go into healthcare to help people, but the realities of retail pharmacy have made it harder for them to spend time doing that,” said Rightway’s Chief Pharmacy Officer, Kristin Devlin, PharmD. “At Rightway, we’re creating a space for pharmacists to return to what they do best: making sure people are getting the treatment that is right for them and helping them navigate questions and concerns along the way.”

“As healthcare becomes increasingly complex, employers are demanding greater accountability, transparency, and value from their healthcare partners,” said Ezra Perlman, Co-President at Francisco Partners. “We believe Rightway is well positioned to meet that demand with a differentiated model that combines aligned incentives, technology, and clinical expertise to help employers better manage pharmacy costs while improving the member experience. We look forward to leveraging our deep expertise in healthcare technology to support Jordan and the Rightway team as they continue to grow and scale the business.”

To learn more about Rightway’s pharmacy benefits and care navigation solutions, visit www.rightwayhealthcare.com.

About Rightway
Rightway is transforming pharmacy benefits and care navigation with a member-first approach that blends expert clinical guidance, high-touch service, and intuitive technology. Rightway delivers personalized, evidence-based support that improves outcomes, drives engagement, and reduces costs. Rightway was the first PBM to integrate pharmacy navigation from clinical experts, guiding members to high-value medications while delivering fully aligned pricing, 100% transparency, and a total spend guarantee. Its care navigation solution simplifies healthcare with proactive, clinician-led support, creating better experiences for members and measurable savings for employers. With Rightway as their healthcare benefits partner, employers don’t have to compromise on employee health, happiness, or their company’s results. Learn more at www.rightwayhealthcare.com.

About Francisco Partners
Francisco Partners is a leading global investment firm that specializes in partnering with technology and technology-enabled businesses. Since its launch over 25 years ago, Francisco Partners has invested in over 500 technology companies, making it one of the most active and longstanding investors in the technology industry. With over $75 billion in capital raised to date, the firm invests in opportunities where its deep sectoral knowledge and operational expertise can help companies realize their full potential. For more information on Francisco Partners, please visit www.franciscopartners.com.

Media Contacts
Rightway
Rita Lebedeva
[email protected] 

Francisco Partners
Prosek Partners
[email protected] 

SOURCE Rightway

New investment arm builds on seven investments, acquisitions and sponsorships across AI, network performance, secure access and IT automation

MONTREAL, Sept. 24, 2026 — Devolutions, a global leader in secure access and IT management solutions, today announced the launch of Devolutions Ventures, a new corporate venture division focused on backing companies and projects across the IT and managed service provider (MSP) ecosystem, including secure access, network performance, automation and other technologies IT teams rely on every day.

Devolutions Ventures builds on seven investments, acquisitions and sponsorships Devolutions has made since 2025, including Mizo, dbatools.pro, Obkio, UniGetUI, Avalonia UI, PowerShell Universal and ControlR, spanning AI automation, network monitoring, open source and IT automation. Rather than pursuing a traditional consolidation strategy, the division is focused on building a connected ecosystem of complementary technologies that address the needs of IT teams and MSPs. Individual investments to date have typically ranged from $500,000 to $3 million per company.

“We’ve spent more than 15 years building technology for IT teams, so we understand both the problems they face and what it takes to build for this market,” said David Hervieux, Chief Executive Officer of Devolutions. “We’re approaching Devolutions Ventures as advisors, not simply investors. We want to back strong teams for the long term, give them room to keep building and use what we’ve learned to help them grow.”

Companies Devolutions invests in continue to operate independently, retaining their existing leadership and product roadmaps. They can also tap into Devolutions’ global community of more than one million IT professionals across 140 countries, along with the company’s experience in go-to-market, security and community building.

“Devolutions brought us much more than capital,” said Mike James, Chief Executing Officer at Avalonia UI. “They understand our customers, our market and what it takes to build a technology company in this space. That combination of investment and operating experience made them a particularly valuable partner as we continue through our next phase of growth.”

Over the next 12 to 18 months, Devolutions Ventures plans to expand the network of investments and partnerships across the IT and MSP ecosystem, building on its activity to date across AI, network technologies, developer tools and open source software.

Founders and developers building technologies for IT teams and MSPs can learn more about Devolutions Ventures at https://devolutions.net/company/ventures/.

About Devolutions
Founded in Canada in 2010, Devolutions develops secure access and IT management solutions designed to help organizations manage privileged access, passwords and remote connections while simplifying and securing IT operations. More than one million users across 140 countries use Devolutions solutions. For more information, visit devolutions.net.

Media Contact
Jenn Zimmer, The Hoffman Agency
[email protected]
408-621-3352

SOURCE Devolutions

In the news release, Basecamp Research raises $140M to advance AI-designed therapeutics, issued 23-Sep-2026 by Basecamp Research over PR Newswire, we are advised by the company that information has changed in the first bulleted subheadline and in the fourth paragraph. The complete, corrected release follows:

Basecamp Research raises $140M to advance AI-designed therapeutics

• Oversubscribed Series C led by S32 with backing from NVIDIA, Menlo Ventures’ Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI, and True Ventures.
• Funding will advance a pipeline of EDEN-designed therapeutics, starting with in vivo cell therapy, and expand pharmaceutical partnerships
• The company has demonstrated strong preclinical results across multiple modalities and disease areas

LONDON and BOSTON, Sept. 23, 2026 — Basecamp Research, a frontier AI company developing AI-designed medicines, today announced a $140M Series C financing to train a new generation of EDEN models and advance a pipeline of AI-designed therapeutics towards clinical development.

Basecamp’s ambition is to develop cures for diseases that remain incurable by designing medicines that reprogram the body to repair itself. The company combines frontier AI models trained on proprietary biological data with technology for writing DNA sequences into cells.

“We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how,” said Glen Gowers, co-founder and CEO of Basecamp Research. “AI-based approaches promise to change what’s possible for patients who currently have few alternatives. This funding brings this technology closer to those who need it most.”

The oversubscribed round was led by S32, with participation from Menlo Ventures’ Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, NVIDIA, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures.

Additional investment comes from senior leaders from across pharma, biotech, and global industry, including André Hoffmann, Vice-Chairman of Roche, who said: “The biotechnology revolution that began fifty years ago transformed how we make medicines. Personalised, AI-designed therapeutics represent the next transformation of that journey. Basecamp Research has built the full platform to deliver it, from biological data to trained models to designed therapies. This will be key in helping the industry to continue to innovate.”

Applying EDEN to develop new therapies

Basecamp Research is applying EDEN, its biological foundation model, to in vivo cell therapy – reprogramming a patient’s cells inside the body. Today’s cell therapies are limited both in the complexity of what they can deliver and by a manufacturing process that costs hundreds of thousands of dollars per patient.

By pairing EDEN’s ability to design long and complex DNA sequences with large serine recombinases that can precisely integrate them into the genome, Basecamp’s platform aims to underpin the future of cell therapies, making them more sophisticated, more customisable and simpler to administer. This has the potential to transform how we treat cancer, autoimmune disease, and more.

The company has demonstrated strong preclinical results across multiple modalities and disease areas. To expand its pharmaceutical partnerships, Basecamp has appointed Richard Pearce, formerly of Biogen, as Chief Business Officer.

Andy Conrad, General Partner at S32 and former CEO of Google’s Verily, who joins the Board of Directors, said: “AI is opening up new possibilities across every part of society, but perhaps nowhere is the potential more meaningful than in human health. The ability to combine AI, biological data and scientific insight could transform how we understand disease, discover medicines and ultimately improve and extend people’s lives. Basecamp Research is building an important technology platform at the center of that opportunity.”

The AI and data powering Basecamp Research’s therapies

At the centre of Basecamp Research’s AI platform is the Trillion Gene Atlas, the world’s largest proprietary biological AI training dataset. Built with partners including NVIDIA, Anthropic, PacBio and Ultima Genomics, the Atlas draws on biological data collected through access and benefit-sharing partnerships in more than 30 countries across all seven continents.

Trained on this data, the company’s EDEN models recognise patterns across a huge breadth of previously unseen biology. Unlike AI systems developed for a single scientific task, EDEN models aim to deliver a universal understanding of how DNA works across all of life.

This means that the models can generate potential therapeutic candidates directly from information about a disease, an approach already demonstrated through Basecamp’s collaboration with Anthropic on Claude Science. The EDEN models’ capabilities include designing cell and gene therapies, enzymes and peptides.

About Basecamp Research

Basecamp Research trains frontier AI models for therapeutic design. The EDEN models are trained on the Trillion Gene Atlas, the world’s largest proprietary genomic dataset, collected through partnerships in more than 30 countries worldwide. Its pipeline of EDEN-designed therapeutics, beginning with in vivo cell therapy, is advancing towards clinical development. Basecamp Research is headquartered in London with offices and labs in Cambridge, MA.